Soleno Therapeutics (SLNO) Share-based Compensation (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Share-based Compensation data on file, last reported at $103.6 million in Q1 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $103.6 million in Q1 2026; TTM through Mar 2026 was $103.6 million, a 62.49% increase from a year earlier, with the FY2025 full-year figure at $95.6 million, up 46.18% from the prior year.
• Share-based Compensation for Q1 2026 stood at $103.6 million, up from $11.5 million in the prior quarter.
• Over the last five years, Share-based Compensation for SLNO reached as high as $103.6 million in Q1 2026 and fell as low as -$4.0 million in Q4 2023.
• Historically, Share-based Compensation has averaged $13.8 million across 5 years, with a median of $2.2 million in 2023.
• Across the five-year window, Share-based Compensation slumped 738.61% in 2023 and soared 2471.47% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $632000.0 in 2022, then plunged by 738.61% to -$4.0 million in 2023, then jumped by 1502.33% to $56.6 million in 2024, then tumbled by 79.73% to $11.5 million in 2025, then soared by 803.15% to $103.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $103.6 million in Q1 2026, $11.5 million in Q4 2025, and $10.0 million in Q3 2025.